Nov. 9 at 8:20 PM
$CGON "Heads up alert! Only three days until Upcoming earnings on Wednesday, 11/12/2025 for
$CGON
Bullish (8.5)
CG Oncology (CGON) has garnered significant attention recently, driven primarily by positive analyst coverage and promising clinical trial results for its lead therapeutic, Cretostimogene.
Guggenheim's initiation of coverage with a ""Buy"" rating and a price target of
$90 reflects strong confidence in the company’s potential, particularly within the non-muscle invasive bladder cancer market, which is characterized by substantial patient demand and pricing power.
CGON has demonstrated impressive momentum, with its stock price surging over 66% in the past 90 days and an 11.55% increase in just the last week, illustrating robust investor interest and market validation.
Financially, CGON's valuation metrics are compelling, particularly when considering its growth potential in a lucrative healthcare sector.
While specific P/E ratios and EPS growth figures were not disclosed, the overall sentiment suggests that CGON is positioned favorably compared to industry peers, especially in light of its promising pipeline and the upcoming FDA review.
Looking ahead, CG Oncology is expected to report earnings soon, with analysts anticipating a continuation of positive trends in revenue and potential earnings surprises.
Historical performance indicates that the company has been able to meet or exceed expectations in previous quarters, which bodes well for upcoming results.
Analyst consensus estimates suggest that CGON may report higher-than-expected revenues, driven by strong demand for its innovative therapies.
This upcoming earnings report could serve as a crucial catalyst for the stock, potentially leading to further price appreciation if results align with bullish analyst forecasts.
The healthcare sector, particularly in oncology, remains strong, with a growing emphasis on innovative treatments and therapies.
CGON's strategic positioning within this sector, alongside its recent performance and analyst support, indicates a favorable outlook for continued growth and investor interest.
- Funds were net buyers of
$CGON during the previous reporting quarter.
- Funds with large holdings in
$CGON include:
- Frazier Life Science, MV:
$20MM. Fund Rank: 56%
- Ensign Peak Advisors, MV:
$10MM. Fund Rank: 67%
- Alyeska Investments, MV:
$4MM. New position. Fund Rank: 79%
- Canada Pension , MV:
$2MM. New position. Fund Rank: 78%
- Last 10 days performance: -9%
- Last 30 days performance: -3%
- Last 90 days performance: 60%
Some of the latest news articles:
- Title: ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates
Publication Date: 11/6/2025 1:10:02 PM, Source: yahoo
URL: https://finance.yahoo.com/news/proqr-prqr-reports-q3-loss-131002685.html?.tsrc=rss
- Title: CG Oncology (CGON) Gets Initiated With a Buy at Guggenheim
Publication Date: 10/18/2025 1:55:02 AM, Source: yahoo
URL: https://finance.yahoo.com/news/cg-oncology-cgon-gets-initiated-015502583.html?.tsrc=rss
- Title: Guggenheim Initiates CG Oncology (CGON) Coverage with
$90 PT, Highlights Bladder Cancer Therapeutic Cretostimogene
Publication Date: 10/16/2025 8:33:13 PM, Source: yahoo
URL: https://finance.yahoo.com/news/guggenheim-initiates-cg-oncology-cgon-203313314.html?.tsrc=rss
- Title: CG Oncology (CGON): Assessing Valuation Following Analyst Coverage and Positive Phase 3 Trial Results
Publication Date: 10/10/2025 12:15:41 AM, Source: yahoo
URL: https://finance.yahoo.com/news/cg-oncology-cgon-assessing-valuation-001541962.html?.tsrc=rss
Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal."
